- All
- Acupuncture
- Back Bone
- Blogs
- Blood Pressure
- Bones and Joints
- Cancer Awareness
- Corona
- Diabetes
- Diet and Health
- FDA
- Health News
- Healthline
- Hepatitis
- Herbal Medicines
- Laser Therapy
- Medical Health Blogs
- Medscape
- Men’s Health
- Mental Wellness
- Nutritional Supplements
- Obesity
- Physical Activity / Exercise /Sports
- Physiotherapy
- Stroke
- Women’s Health
June 30, 2022
Zelnorm (tegaserod), an oral short-term treatment of irritable bowel syndrome and constipation (IBS-C), is being removed from the US market effective June 30, according to the […]
June 29, 2022
Adults younger than 55 years were least likely to get screened for colorectal cancer over the past 2 decades, particularly if they were Hispanic or Asian […]
June 28, 2022
A randomized clinical trial indicated that add-on baclofen may be of benefit to patients on adequate doses of proton pump inhibitors (PPI) with refractory gastroesophageal reflux […]
June 28, 2022
LONDON — The novel liver-targeting agent fazirsiran has fared well in a small, but significant, study looking at its ability to improve liver histology in adults with […]
June 24, 2022
The American Gastroenterological Association has issued new guidelines for the medical treatment of irritable bowel syndrome (IBS). The guidelines, which are separated into one publication for […]
June 24, 2022
LONDON ― Case numbers of acute hepatitis in children show “a declining trajectory,” and COVID-19 and adenovirus remain the most likely, but as yet unproven, causative […]
June 22, 2022
What we eat affects the trillions of bacteria, fungi, viruses, and other germs that live in our digestive tract and our diet shapes what scientists call […]
June 20, 2022
Oregon and Kentucky recently enacted policies to eliminate financial disincentives that may have deterred people from undergoing a follow-up colonoscopy after a positive result on a […]
June 17, 2022
The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi, AbbVie) for a third indication — treatment of moderately to severely active Crohn’s disease in […]